CA2827373C - Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea - Google Patents

Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea Download PDF

Info

Publication number
CA2827373C
CA2827373C CA2827373A CA2827373A CA2827373C CA 2827373 C CA2827373 C CA 2827373C CA 2827373 A CA2827373 A CA 2827373A CA 2827373 A CA2827373 A CA 2827373A CA 2827373 C CA2827373 C CA 2827373C
Authority
CA
Canada
Prior art keywords
cream
oxymetazoline
pharmaceutically acceptable
acid
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2827373A
Other languages
English (en)
French (fr)
Other versions
CA2827373A1 (en
Inventor
Stuart D. Shanler
Christopher Powala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EPI Health LLC
Original Assignee
Aclaris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aclaris Therapeutics Inc filed Critical Aclaris Therapeutics Inc
Publication of CA2827373A1 publication Critical patent/CA2827373A1/en
Application granted granted Critical
Publication of CA2827373C publication Critical patent/CA2827373C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
CA2827373A 2011-02-15 2012-02-14 Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea Active CA2827373C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161443210P 2011-02-15 2011-02-15
US61/443,210 2011-02-15
PCT/US2012/025068 WO2012112566A1 (en) 2011-02-15 2012-02-14 Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea

Publications (2)

Publication Number Publication Date
CA2827373A1 CA2827373A1 (en) 2012-08-23
CA2827373C true CA2827373C (en) 2019-05-14

Family

ID=45757218

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2827373A Active CA2827373C (en) 2011-02-15 2012-02-14 Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea

Country Status (11)

Country Link
US (4) US20120208858A1 (enExample)
EP (2) EP3578178A1 (enExample)
JP (3) JP6225030B2 (enExample)
KR (2) KR102058756B1 (enExample)
CN (2) CN107007546A (enExample)
AU (3) AU2012217858A1 (enExample)
BR (1) BR112013020770A2 (enExample)
CA (1) CA2827373C (enExample)
ES (1) ES2742273T3 (enExample)
RU (1) RU2648439C2 (enExample)
WO (1) WO2012112566A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
AU2012217858A1 (en) * 2011-02-15 2013-09-05 Allergan, Inc. Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
JP6174579B2 (ja) * 2011-08-04 2017-08-02 オメロス コーポレーション 安定な注射用抗炎症性溶液
CN104093404B (zh) 2011-09-20 2016-12-07 阿勒根公司 用于治疗老花眼、轻度远视和不规则散光的组合物和方法
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
FR3000395A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee
JP6436354B2 (ja) 2013-02-01 2018-12-12 オキュフィア・ファーマ・インコーポレイテッドOcuphire Pharma, Inc. 視機能を改善するためのフェントラミンの連日眼科投与のための方法および組成物
PT2950648T (pt) 2013-02-01 2020-01-06 Ocuphire Pharma Inc Soluções oftálmicas aquosas de fentolamina e usos médicos
EP3062888A1 (en) * 2013-10-28 2016-09-07 Cipher Pharmaceuticals Compositions for dermatological use
EP3137055A4 (en) * 2014-05-01 2017-12-06 Anterios, Inc. Demonstrable efficacy across or within patient populations
US9801857B2 (en) 2014-06-11 2017-10-31 Allergan, Inc. Stabilized oxymetazoline formulations and their uses
US20180256487A1 (en) * 2015-09-17 2018-09-13 June Jacobs Laboratories, Llc Compositions and methods for the treatment and prevention of radiation dermatitis
EP3476393A4 (en) * 2016-06-28 2019-07-17 Doris Maria Hexsel USE OF AN ACTIVE AGENT FOR THE TREATMENT OF TELANGIEKTATISCHEM MELASMA
BR112019010131A2 (pt) 2016-11-21 2019-10-08 Eirion Therapeutics Inc entrega transdérmica de agentes grandes
US11191767B2 (en) 2017-11-15 2021-12-07 Boris Slavinovich FARBER Pharmaceutical composition for stimulating stem cell division and suppressing bacterial virulence
MX368750B (es) * 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
US12161629B2 (en) 2018-10-15 2024-12-10 Opus Genetics, Inc. Methods and compositions for treatment of glaucoma and related conditions
CN113164452A (zh) 2018-10-26 2021-07-23 奥库菲尔制药股份有限公司 治疗老花眼、散瞳和其他眼部疾病的方法和组合物
AU2019390704A1 (en) * 2018-11-26 2021-06-03 Cellix Bio Private Limited Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases
CA3133733A1 (en) * 2019-04-30 2020-11-05 Xin-Yuan Fu Compounds for treating inflammation induced autoimmune skin diseases and uses thereof
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
KR102633256B1 (ko) * 2021-10-08 2024-02-05 (주)우리스마트바이오 참당귀 추출물을 이용한 피부개선용 화장품 조성물, 이를 포함한 피부개선용 화장품 및 피부개선용 화장품 제조방법
US20250114362A1 (en) * 2022-01-05 2025-04-10 Asymmetric Therapeutics, Llc Methods and compositions for treatment of cutaneous proliferative disorders and other skin conditions
US20240423959A1 (en) * 2022-06-21 2024-12-26 Jjr&D, Llc Topical benzimidazole formulations and methods for use in treating inflammatory dermatoses

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3147275A (en) 1964-09-01 Nh-cha
US8093293B2 (en) * 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US6433024B1 (en) 2000-05-08 2002-08-13 Karl F. Popp Topical anti-acne composition
BRPI0113271B1 (pt) 2000-08-16 2016-01-26 Dolby Lab Licensing Corp método para modificar a operação da função codificadora e/ou da função decodificadora de um sistema de codificação perceptual de acordo com informação suplementar
US6479060B1 (en) * 2001-09-04 2002-11-12 Healthpoint, Ltd. Elegant hydrogenated castor oil ointments
US6824786B2 (en) 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US6573301B1 (en) 2002-04-23 2003-06-03 Bradley Pharmaceuticals, Inc. Carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
CN104490884A (zh) * 2004-05-25 2015-04-08 桑斯罗萨医药发展公司 治疗或预防炎症性皮肤疾病的化合物、制剂及方法
US8147875B2 (en) 2005-03-15 2012-04-03 Campina Nederland Holding B.V. Dermatologic use of milk proteins
BRPI0608951A2 (pt) * 2005-03-30 2010-02-17 Revance Therapeutics Inc composições e método para o tratamento de acne
JP5129130B2 (ja) 2005-06-29 2013-01-23 ディーエスエム アイピー アセッツ ビー.ブイ. イソフラボンのナノ粒子を含む局所組成物
CN101460060A (zh) * 2006-03-01 2009-06-17 特莱斯特拉塔公司 局部治疗焦油响应性皮肤病用的组合物和方法
US20080031979A1 (en) * 2006-08-04 2008-02-07 Claude Saliou Use of extracts for the treatment of viral disorders
RU2310439C1 (ru) * 2006-10-05 2007-11-20 Закрытое акционерное общество Фармацевтическое научно-производственное предприятие "Ретиноиды" (ЗАО "Ретиноиды") Мазевая акарицидная композиция и способ лечения демодекоза и сопутствующих ему заболеваний
US9511016B2 (en) * 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
US20090061020A1 (en) 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
SI2818184T1 (sl) 2007-11-16 2019-03-29 Aclaris Therapeutics, Inc. Sestava in postopki za zdravljenje purpure
US20090130029A1 (en) * 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
US20110224216A1 (en) 2009-10-26 2011-09-15 Galderma Laboratories Inc. Methods of Treating or Preventing Acute Erythema
US20120082625A1 (en) 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
EP2645993B1 (en) 2010-12-03 2016-11-02 Allergan, Inc. Pharmaceutical cream compositions comprising oxymetazoline
AU2012217858A1 (en) 2011-02-15 2013-09-05 Allergan, Inc. Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
WO2013010032A1 (en) 2011-07-14 2013-01-17 Allergan, Inc. Gel compositions of oxymetazoline and methods of use

Also Published As

Publication number Publication date
AU2017202726A1 (en) 2017-05-18
RU2013141845A (ru) 2015-03-27
JP2018193399A (ja) 2018-12-06
CN103458897A (zh) 2013-12-18
KR20140020912A (ko) 2014-02-19
AU2019203993A1 (en) 2019-06-27
US11541000B2 (en) 2023-01-03
CA2827373A1 (en) 2012-08-23
EP3578178A1 (en) 2019-12-11
EP2675449B1 (en) 2019-04-24
KR102058756B1 (ko) 2020-01-22
AU2012217858A1 (en) 2013-09-05
AU2017202726B2 (en) 2019-03-07
JP2014505733A (ja) 2014-03-06
WO2012112566A1 (en) 2012-08-23
AU2019203993B2 (en) 2020-05-28
JP2017066162A (ja) 2017-04-06
US20200276108A1 (en) 2020-09-03
US20190167566A1 (en) 2019-06-06
EP2675449A1 (en) 2013-12-25
US20140113947A1 (en) 2014-04-24
KR20190114010A (ko) 2019-10-08
ES2742273T3 (es) 2020-02-13
CN107007546A (zh) 2017-08-04
US20120208858A1 (en) 2012-08-16
JP6389534B2 (ja) 2018-09-12
BR112013020770A2 (pt) 2019-08-27
RU2648439C2 (ru) 2018-03-26
JP6225030B2 (ja) 2017-11-01

Similar Documents

Publication Publication Date Title
US11541000B2 (en) Pharmaceutical cream compositions of oxymetazoline and methods of use
AU2018229508B2 (en) Pharmaceutical cream compositions comprising oxymetazoline
US20130079379A1 (en) Gel compositions of oxymetazoline and methods of use
HK1192724B (en) Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
HK1192724A (en) Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
HK1190307B (en) Pharmaceutical cream compositions comprising oxymetazoline

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170127